Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (DE:ICY)
FRANKFURT:ICY
Incyte (ICY) Stock Price & Analysis
0 Followers
ICY Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€47.11 - €68.70
Previous Close€47.59
Volume0.00
Average Volume (3M)120.00
Market Cap
€10.83B
Enterprise Value€7.46B
Total Cash (Recent Filing)$3.66B
Total Debt (Recent Filing)$32.60M
Price to Earnings (P/E)19.5
Beta0.09
Next Earnings
Apr 30, 2024EPS Estimate
€0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.44
Shares Outstanding224,526,128
10 Day Avg. Volume34
30 Day Avg. Volume120
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.34
Price to Sales (P/S)10.44
Price to Cash Flow (P/CF)19.50
P/FCF Ratio19.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.09
Enterprise Value/Gross Profit2.17
Enterprise Value/Ebitda7.55
Forecast
1Y Price Target
€66.31Price Target Upside39.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Incyte News
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsINCY acquires Escient Pharmaceuticals, enhancing its inflammation and autoimmunity portfolio with promising new treatments.
Market ExpansionAcquired small molecules have the potential to offer patients once-daily oral treatments for inflammatory indications in the multi-billion dollar inflammation and autoimmune space.
Product Safety And EfficacyBoth EP262 and EP547 have shown no serious adverse events in early trials, indicating a potentially better safety profile for these treatments.
Bears Say
Acquisition ConcernsThe acquisition of Escient Pharmaceuticals is viewed as very early and costly with a potential launch for the acquired assets only by 2029, which may not align with investor expectations for timely returns.
Financial FlexibilityIncyte's cash position will decrease by approximately $3 billion post-acquisition, impacting financial flexibility and potentially affecting the company's ability to invest in other strategic opportunities.
Patent Cliff RisksThere are concerns about Incyte's ability to address the large revenue gap due to the loss of exclusivity of Jakafi in 2028, raising questions about the company's future earnings potential.
---
Options Prices
Currently, No data available
---
Ownership Overview
30.68% Insiders
22.05% Mutual Funds
27.55% Other Institutional Investors
19.71% Public Companies and
Individual Investors
ICY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was €47.11 and its highest was €68.70 in the past 12 months.
What is Incyte Corp’s market cap?
Currently, no data Available
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Apr 30, 2024 which is yesterday.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Feb 13, 2024. The company reported €0.988 earnings per share for the quarter, missing the consensus estimate of €1.072 by -€0.084.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is €0.76.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 224,526,120 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of €0.988 in its last earnings report, missing expectations of €1.072. Following the earnings report the stock price went up 1.987%.
Which hedge fund is a major shareholder of Incyte Corp?
Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
---
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€66.31 (39.33% Upside)
€66.31 (39.33% Upside)
Blogger Sentiment
Bullish
DE:ICY Sentiment 87%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.71%
12-Months-Change
Fundamentals
Return on Equity
12.50%
Trailing 12-Months
Asset Growth
15.96%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
ICY Company Deck
---
ICY Earnings Call
Q4 2024
0:00 / 0:00
---
ICY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
ICY Stock 12 Months Forecast
Average Price Target
€66.31
▲(39.33% Upside)
Technical Analysis
Best Analysts Covering ICY
1 Year
1 Year Success Rate
15/23 ratings generated profit
1 Year Average Return
+7.58%
reiterated a buy rating 2 months ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +7.58% per trade.
---